Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women

Journal of Bone and Mineral Research

Volumn 27, Issue 2, 2012, Pages 255-262

  Fitzpatrick, Lorraine A ^a   Dabrowski, Christine E ^a   Cicconetti, Gregory ^a   Gordon, David N ^a   Fuerst, Thomas ^b,e   Engelke, Klaus ^b,c,e   Genant, Harry K ^b,d,e  

^a GLAXOSMITHKLINE   (United States)

^b SYNARC INC   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NONE

Author keywords

CALCIUM SENSING RECEPTOR ANTAGONIST; PARATHYROID HORMONE; RONACALERET

Indexed keywords

ALENDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RONACALERET;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BONE DENSITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; FEMALE; FEMUR; HIP; HUMAN; HYPERPARATHYROIDISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OSTEOLYSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPINE; TRABECULAR BONE; TREATMENT DURATION;

EID: 84856200881     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.554     Document Type: Article

References (25)

1. Rosen CJ,. Clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2005; 353: 595-603.
2. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ,. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100: 1475-80. (Pubitemid 27425772)
3. Dufresne TE, Chmielewski PA, Manhart MD, Johnson TD, Borah B,. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int. 2003; 73: 423-32. (Pubitemid 37466634)
4. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH,. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344: 1434-41. (Pubitemid 32402100)
5. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ,. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000; 85: 2129-34. (Pubitemid 32269232)
6. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R,. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001; 16: 1846-53. (Pubitemid 32911491)
7. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF,. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18: 1932-41. (Pubitemid 37377441)
8. Misof BM, Roschger P, Cosman F, Kurland ES, Tesch W, Messmer P, Dempster DW, Nieves J, Shane E, Fratzl P, Klaushofer K, Bilezikian J, Lindsay R,. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. J Clin Endocrinol Metab. 2003; 88: 1150-6. (Pubitemid 36337769)
9. Genant HK, Jiang Y,. Advanced imaging assessment of bone quality. Ann NY Acad Sci. 2006; 1068: 410-28. (Pubitemid 43824171)
10. Engelke K, Adams JE, Armbrecht G, Augat P, Bogado CE, Bouxsein ML, Felsenberg D, Ito M, Prevrhal S, Hans DB, Lewiecki EM,. Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom. 2008; 11 (1): 123-62. (Pubitemid 351602191)
11. Riggs BL, Melton LJ III, Robb RA, Camp JJ, Atkinson EJ, Peterson JM, Rouleau PA, McCollough CH, Bouxsein ML, Khosla S,. Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites. J Bone Miner Res. 2004; 19: 1945-54. (Pubitemid 41103408)
12. Nemeth EF,. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Design. 2002; 8: 2077-87. (Pubitemid 34982171)
13. Kumar S, Matheny CJ, Hoffman SJ, Marquis RW, Schultz M, Liang X, Vasko JA, Stroup JB, Vaden VR, Haley H, Fox J, DelMar EG, Nemeth EF, Lago AM, Callahan JF, Bhatnagar P, Huffman WF, Gowen M, Yi B, Danoff TM, Fitzpatrick LA,. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone. 2010; 46: 534-42.
14. Fitzpatrick LA, Dabrowski CE, Cicconetti G, Gordon DN, Papapoulos S, Bone HG, Bilezikian JP,. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone density. J Clin Endocrinol Metab. 2011; 96: 2441-9.
15. Genant HK, Cann CE, Ettinger B, Gordan GS,. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med. 1982; 97: 699-705. (Pubitemid 13251641)
16. Kalender WA, Brestowsky H, Felsenberg D,. Bone mineral measurements: automated determination of the midvertebral CT section. Radiology. 1988; 168: 219-21.
17. Engelke K, Mastmeyer A, Bousson V, Fuerst T, Laredo JD, Kalender WA,. Reanalysis precision of 3D quantitative computed tomography (QCT) of the spine. Bone. 2009; 44: 566-72.
18. Kang Y, Engelke K, Kalender WA,. A new accurate and precise 3-D segmentation method for skeletal structures in volumetric CT data. IEEE Trans Med Imaging. 2003; 22: 586-98.
19. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ,. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003; 349: 1207-15. (Pubitemid 37152030)
20. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF,. Opposite bone remodelling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005; 165: 1762-8. (Pubitemid 41138965)
21. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL,. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women. J Bone Miner Res. 2003; 18: 539-43. (Pubitemid 36241071)
22. Dobnig H, Turner RT,. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997; 138: 4607-12. (Pubitemid 27460894)
23. Parisien M, Cosman F, Mellish RWE, Schnitzer M, Nieves J, Silverberg SJ, Shane E, Kimmel D, Recker RR, Bilezikian JB, Lindsay R, Dempster DW,. Bone structure in postmenopausal hyperparathyroid, osteoporotic and normal women. J Bone Miner Res. 1995; 10: 1393-9.
24. Dempster DW, Muller R, Zhou H, Kohler T, Shane E, Parisien M, Silverberg SJ, Bilezikian JB,. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone. 2007; 41: 19-24. (Pubitemid 46891902)
25. Dempster DW, Parisien M, Silverberg SJ, Liang X-G, Schnitzer M, Shen V, Shane E, Kimmel DB, Recker R, Linday R, Bilezikian JP,. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J Clin Endocrinol Metab. 1999; 84: 1562-6. (Pubitemid 30644254)